Chemical subgroup
J05AX – Andere antivirale Mittel
9Decisions
12Patient groups
Added benefit by patient group
- Considerable1
- Minor1
- Non-quantifiable2
- Not proven8
Decisions, newest first
- 2026-02-19HepcludexBulevirtidNot proven: 2 of 2 patient groups
- 2025-11-06PrevymisLetermovirNot proven
- 2025-11-06PrevymisLetermovirNon-quantifiable
- 2024-06-06PrevymisLetermovirNon-quantifiable
- 2024-06-06PrevymisLetermovirNot proven
- 2023-06-01LivtencityMaribavirMinor
- 2021-09-16RukobiaFostemsavirNot proven
- 2021-08-05XofluzaBaloxavir marboxilConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-08-05XofluzaBaloxavir marboxilNot proven: 2 of 2 patient groups
Data status: 2026-10-29